Welcome to EGB Advisors
Essentially "Drug Hunting" to us is an arbitrage of geography or time to create new
value from existing molecules, with new intellectual property and new important
benefits to patients.
EGB was founded on our in-licensing of clinical-stage small molecule therapeutics
("drug hunting") practice for clients such as CoTherix (Actelion) and ChemGenex
(Cephalon/Teva). Historically we have also worked on behalf of technology transfer
offices such as for the Kauffman Foundation in its
efforts to improve commercialization of technology and the M.D. Anderson Cancer Center.
In 2004, EGB began to develop our own portfolio companies after reviewing
over 1,000 technologies. Only two met our proprietary criteria, and we formed
Inverseon, Inc. and Urigen Pharmaceuticals, Inc.
Inverseon, Inc. is poised to transform important pulmonary diseases. In 2010, the
Chairman of an FDA review panel said that Inverseon's approach has the potential
to replace the best selling class of pulmonary drugs worldwide. In 2011, Inverseon
was commended for our potential to advance the treatment of COPD by Medical
Futures in the UK. Dr. Garner founded Inverseon in 2004 with Dr. Franklin and
served as principal investigator on Inverseon's STTR grants while raising private
capital. On Aug 30, 2012, Inverseon merged with CBio to become a public company
called Invion Limited (ASX: IVX)
The paradigm of local treatment of IC/PBS was industrialized by Urigen through
incubation at EGB.Urigen completed a multi-center double-blind, placebo-controlled
clinical trial of URG101 for Interstitial Cystitis/Painful Bladder Syndrome (IC/
PBS) with statistical significance on the primary pain endpoint and all secondary
measures of response. Dr. Garner founded Urigen and took it public in 2007.
In 2010 we founded DelMar Pharmaceuticals, Inc. of Vancouver, Canada
(www.delmarpharma.com) to reposition a drug approved in China after modern
biologics fail. DelMar has opened a clinical trial of VAL-083 in Glioblastoma
(primary brain tumors) after Avastin®. DelMar follows the business model
of ChemGenex, founded by Dr. Brown. ChemGenex was acquired in 2011 for
approximately $350M including European rights.